AcuamarkDx is pleased to announce the addition of Tim Gordon and Chiara Gabbi, MD, PhD, to ourboard of directors. Their expertise in financial strategy and clinical research will help guide us as we advance our groundbreaking early cancer detection technology through clinical development and toward commercialization.

Mr. Gordon brings 40 years of experience in audit and financial advisory services at Ernst & Young, where he supported health and life sciences companies through IPOs, mergers and acquisitions, and other pivotal financial transitions. Dr. Gabbi is a distinguished physician-scientist with over 20 years of experience in clinical and translational medicine, specializing in cancer, personalized medicine, and genomics.

To learn more, please visit the official press release.

Contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.. 

Acuamark Diagnostics, Inc. 
101 Avenue Of the Americas, Fl 3, JLabs 
New York, NY, 10013 
USA 

The round was led by Claudio Del Vecchio and joined by Bruker Corporation. 

New York, NY, July 19, 2022 – Acuamark Diagnostics (“AcuamarkDx”), an early cancer detection company, today announced the closing of an $11.3 million Series A round.  

TAMPA, Fla., Dec. 13, 2016 /PRNewswire/ -- The National Academy of Inventors (NAI) has named 175 leaders of academic invention to NAI Fellow status.

In a recent discussion on diagnostic company funding, Acuamark CEO Bernard Peperstraete highlighted advances in blood-based diagnostics technologies.

While the industry has a lot to be proud of, especially with respect to late-stage disease detection, Acuamark has engineered the first-ever qPCR-based approach optimized for highly accurate early cancer signal detection at ultra-low abundance.

NEW YORK —  June 1, 2021 — Acuamark Diagnostics, Inc. (“AcuamarkDx”), a biotechnology company that revolutionizes the global fight against cancer with first-in-kind early-cancer detection technology, today announced that Dr. Cedric Francois has joined its Board of Directors.

Successful public biotech entrepreneur and CEO joins AcuamarkDx's Board of Directors as company prepares for next phase of development.

October 13, 2016 - In its early stages, cancer is usually asymptomatic. Early detection is a complex challenge. Can a blood sample detect early signs?

BY ENMEDIA

AcuamarkDx is a cancer diagnostics company making early cancer detection the new standard of primary care. Frequent monitoring and screening are the standard of care for diseases such as diabetes and heart disease. Why can’t this be true for cancer? At present, no early cancer diagnostic is both sensitive and specific. The AcuamarkDx technology uses optimized qPCR to detect low-abundance methylation markers, allowing for both sensitive and specific detection of cancer at early stages. The company’s initial product will focus on colorectal cancer, with a pan-cancer screening test to follow. With the implementation of its tests, AcuamarkDx hopes to prevent 5 million cancer deaths annually by providing earlier cancer detection for all.

NEW YORK — Apr 21, 2020 — Acuamark Diagnostics, Inc. (“AcuamarkDx”), a biotechnology company that focuses on developing innovative blood-based screening assays for reliable and cost-effective detection of early-stage cancer, today announced the appointment of William Gedale as its Executive Chairman. Mr. Gedale will replace Mr. Michael Gargano as Chairman of the Company.

NEW YORK (GenomeWeb) – October 13, 2016 - iCareDx announced that it was rebranding itself as Acuamark Diagnostics as it works to raise funds for its first round of clinical testing.

Acuamark Diagnostics is pleased to announce Giulia Kennedy, Ph.D., has joined our board of directors. Dr. Kennedy brings more than two decades of experience developing novel diagnostic technologies, most recently as global chief scientific officer and chief medical officer at Veracyte, a cancer genetics company.

NEW YORK — Dec 27, 2019 — Acuamark Diagnostics, Inc. (“Acuamark”), a biotechnology company that focuses on developing innovative blood-based screening assays for reliable and cost-effective detection of early-stage cancer, today announced that it has completed private placement of its Preferred Series AA3 stock in a round that was substantially oversubscribed. The proceeds will be used to fund expansion of its CRC pilot program entering proof of concept stage in clinical samples and expand the company’s “all-cancer screening” program’s research and development. 

September, 22 2016 - Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.